Analysts Set DaVita Inc. (NYSE:DVA) Price Target at $148.00

DaVita Inc. (NYSE:DVA) has earned an average rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $148.00.

Several equities analysts have recently weighed in on DVA shares. Truist Financial set a $140.00 target price on shares of DaVita in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday. TD Cowen dropped their target price on DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Barclays decreased their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 30th.

DaVita Price Performance

Shares of DVA opened at $115.18 on Wednesday. DaVita has a 1 year low of $113.97 and a 1 year high of $179.60. The stock’s fifty day moving average price is $121.38 and its two-hundred day moving average price is $131.48. The firm has a market cap of $8.13 billion, a PE ratio of 11.86, a PEG ratio of 0.88 and a beta of 1.00.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The firm had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. During the same quarter in the previous year, the company posted $2.59 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Sell-side analysts anticipate that DaVita will post 10.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several hedge funds have recently bought and sold shares of DVA. Hantz Financial Services Inc. lifted its stake in DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Mid American Wealth Advisory Group Inc. bought a new position in shares of DaVita in the second quarter worth $36,000. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita in the second quarter worth $43,000. iSAM Funds UK Ltd bought a new stake in DaVita during the third quarter valued at $46,000. Finally, Ameritas Advisory Services LLC purchased a new position in DaVita during the second quarter worth about $47,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.